Why the study?
How should patients treated with direct oral anticoagulants be managed periprocedurally in dental practice?
How should patients treated with direct oral anticoagulants be managed periprocedurally in dental practice?
This review summarizes the periprocedural management of patients on direct oral anticoagulants undergoing dental procedures.
Answers are grounded in this paper and cite their sources.
Provides a synthesized framework for DOAC management during dental procedures; leaves open the need for prospective validation before.
The direct oral anticoagulant drugs (DOAC) are generally safe and effective in several clinical settings including acute venous thromboembolic disease, prophylaxis in the postoperative setting, prevention of thromboembolism in patients with non-valvular atrial fibrillation, and in the management of acute coronary syndrome. The relatively short half-life, rapid onset of action, and predictable pharmacokinetics should simplify periprocedural use of the DOAC. The aim of this work is to propose and summarize periprocedural management of patients treated with the DOAC in dental practice and to inform about the principal specifications of this treatment.
No takes yet. Share an insight, caveat, or question.
Staško et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: